Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

REVEALED: Is this penny stock s 525 upside potential an attainable goal - The Real Truth

A smart investment strategy is to diversify your portfolio with both stable, established companies and growth stocks. Growth stocks, particularly those from the biotech industry, are often in the early stages of development. As a result, while these companies are risky, they also have more room for expansion. One such company is Skye Bioscience (SKYE), a clinical-stage biopharmaceutical company developing new therapeutic pathways for metabolic health.

Skye stock has earned a “Strong Buy” rating on Wall Street, with a forecast of over 500% upside from current levels. This optimistic outlook is primarily due to the company’s lead candidate nimacimab for obesity. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.